Hutchison China MediTech Limited (HCM): Price and Financial Metrics

Hutchison China MediTech Limited (HCM): $37.54

-0.87 (-2.27%)

POWR Rating

Component Grades













Add HCM to Watchlist
Sign Up

Industry: China


of 62

in industry


  • Sentiment is the dimension where HCM ranks best; there it ranks ahead of 90.29% of US stocks.
  • The strongest trend for HCM is in Value, which has been heading up over the past 31 weeks.
  • HCM's current lowest rank is in the Quality metric (where it is better than 8.18% of US stocks).

HCM Stock Summary

  • Of note is the ratio of HUTCHMED (China) Ltd's sales and general administrative expense to its total operating expenses; just 12.72% of US stocks have a lower such ratio.
  • HCM's price/sales ratio is 18.64; that's higher than the P/S ratio of 89.1% of US stocks.
  • With a year-over-year growth in debt of 393.03%, HUTCHMED (China) Ltd's debt growth rate surpasses 96.86% of about US stocks.
  • Stocks that are quantitatively similar to HCM, based on their financial statements, market capitalization, and price volatility, are OCFT, TARO, AUMN, VNE, and NEON.
  • Visit HCM's SEC page to see the company's official filings. To visit the company's web site, go to

HCM Stock Price Chart Interactive Chart >

Price chart for HCM

HCM Price/Volume Stats

Current price $37.54 52-week high $43.94
Prev. close $38.41 52-week low $23.67
Day low $37.38 Volume 381,000
Day high $38.08 Avg. volume 306,195
50-day MA $39.87 Dividend yield N/A
200-day MA $32.77 Market Cap 6.49B

Hutchison China MediTech Limited (HCM) Company Bio

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.

HCM Latest News Stream

Event/Time News Detail
Loading, please wait...

HCM Latest Social Stream

Loading social stream, please wait...

View Full HCM Social Stream

Latest HCM News From Around the Web

Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (“FL”), a subtype of non-Hodgkin’s lympho

Yahoo | September 13, 2021

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SANOVO, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase i

Yahoo | September 8, 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMPL-689), savolitinib (ORPATHYS® in China) and fruquintinib (ELUNATE® in China) will be presented at the upcoming 2021 European Society for Medical Oncology (“ESMO”) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known

Yahoo | September 7, 2021

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary shares, which trade on The Stock Exchange of Hong Kong Limited (“HKEX”), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on September 6, 2021, according to announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange

Yahoo | September 6, 2021

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for the addition of a highly selective vascular endo

Yahoo | August 26, 2021

Read More 'HCM' Stories Here

HCM Price Returns

1-mo -6.89%
3-mo 28.56%
6-mo 29.36%
1-year 10.38%
3-year 32.88%
5-year 201.04%
YTD 17.24%
2020 27.72%
2019 8.58%
2018 -41.43%
2017 190.49%
2016 N/A

Continue Researching HCM

Want to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:

Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.4838 seconds.